New shot aims to ease gout flare pain in early trial

NCT ID NCT06444867

First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 44 times

Summary

This early-phase trial tested a single injection of LEO 158968 in 6 people experiencing a gout flare. The main goal was to see if the drug could reduce joint pain to none or mild within a few days. Researchers also monitored safety and how the body processed the drug. Because it is a very small study, results are preliminary and not conclusive.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for JOINT PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • LEO Pharma Investigational Site

    Lille, 59400, France

  • LEO Pharma Investigational Site

    Venlo, 5912 BL, Netherlands

  • LEO Pharma Investigational Site

    London, EC2Y 8EA, United Kingdom

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

LEO 158968 (a drug given as a shot under the skin)

What this could lead to

If it works, this could point toward a new option for quickly reducing pain during a gout flare.

What could go wrong

This is a very early, tiny trial with only 6 people. It is not designed to prove effectiveness, and the drug may not work or could have side effects.

Conditions

The condition(s) this trial relates to.

Arthralgia arthritic joint disease gout

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.